Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55–56
HOS-110615 · Präparat HOS-093385
55 Medicinal product by Effects on drug levels Recommendation therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning (dose in mg) co-administration with 245 mg tenofovir disoproxil Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma (400 mg/100 mg q.d.) + AUC: ↓ 29% concentrations of tenofovir Lopinavir/Ritonavir Cmax: ↓ 41% resulting from (800 mg/200 mg q.d.) + co-administration of tenofovir Emtricitabine/Tenofovir GS-3310072: disoproxil, disoproxil AUC: ↔ sofosbuvir/velpatasvir and (200 mg/245 mg q.d.) Cmax: ↔ lopinavir/ritonavir may Cmin: ↔ increase adverse reactions related to tenofovir disoproxil, Velpatasvir: including renal disorders. The AUC: ↔ safety of tenofovir disoproxil Cmax: ↓ 30% when used with Cmin: ↑ 63% sofosbuvir/velpatasvir and a pharmacokinetic enhancer Lopinavir: (e.g. ritonavir or cobicistat) AUC: ↔ has not been established. Cmax: ↔ Cmin: ↔ The combination should be used with caution with Ritonavir: frequent renal monitoring (see AUC: ↔ section 4.4). Cmax: ↔ Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage f429fcd15aa6871cb839634b36d3ad1413e88ea18aacf119f35aa295ac448c15 · Zeichen 26038–28373 im Abschnitt